MedTrace Logo

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

NCT03262545 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-08-28

No results posted yet for this study

Summary

The study is to investigate the efficacy and safety of apatinib in patients with advanced ovarian cancer,who has received second-line chemotherapy and failed.

Conditions

  • Angiogenesis Inhibitors，Ovarian Neoplasms

Interventions

DRUG

apatinib

Patients in experimental group will take 500mg apatinib daily orally，and patients in control group will take placebo

DRUG

Placebos

Physical properties of placebos are consistent with apatinib

Sponsors & Collaborators

  • Sichuan Cancer Hospital and Research Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-27
Primary Completion
2020-08-31
Completion
2021-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03262545 on ClinicalTrials.gov